Key result
Diabetes was associated with a significantly higher in-hospital mortality compared to non-diabetes (9.1% vs 4.8%, adjusted OR 1.70) in patients with STEMI undergoing primary percutaneous coronary intervention.
Why the study?
Diabetes has historically been associated with higher mortality in STEMI treated with PPCI, but its impact on time delays, reperfusion, and mortality in a contemporary population, including during the COVID pandemic, needed evaluation.
Does diabetes increase in-hospital and 30-day mortality in STEMI patients undergoing primary PCI?
Cohort (n=16,083)
Yes
Does diabetes increase in-hospital and 30-day mortality in STEMI patients undergoing primary PCI?
In a contemporary STEMI population undergoing primary PCI, diabetes is significantly associated with impaired epicardial reperfusion and higher in-hospital and 30-day mortality, particularly during the COVID-19 pandemic.
May warrant intensified monitoring in diabetic STEMI; leaves open whether targeted interventions improve survival.
BACKGROUND AND AIM: Diabetes has been shown in last decades to be associated with a significantly higher mortality among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI (PPCI). Therefore, the aim of current study was to evaluate the impact of diabetes on times delays, reperfusion and mortality in a contemporary STEMI population undergoing PPCI, including treatment during the COVID pandemic. METHODS AND RESULTS: The ISACS-STEMI COVID-19 is a large-scale retrospective multicenter registry involving PPCI centers from Europe, Latin America, South-East Asia and North-Africa, including patients treated from 1st of March until June 30, 2019 and 2020. Primary study endpoint of this analysis was in-hospital mortality. Secondary endpoints were postprocedural TIMI 0-2 flow and 30-day mortality. Our population is represented by 16083 STEMI patients. A total of 3812 (23,7 %) patients suffered from diabetes. They were older, more often males as compared to non-diabetes. Diabetic patients were less often active smokers and had less often a positive family history of CAD, but they were more often affected by hypertension and hypercholesterolemia, with higher prevalence of previous STEMI and previous CABG. Diabetic patients had longer ischemia time, had more often anterior MI, cardiogenic shock, rescue PCI and multivessel disease. They had less often out-of-hospital cardiac arrest and in-stent thrombosis, received more often a mechanical support, received less often a coronary stent and DES. Diabetes was associated with a significantly impaired postprocedural TIMI flow (TIMI 0-2: 9.8 % vs 7.2 %, adjusted OR [95 % CI] = 1.17 [1.02-1.38], p = 0.024) and higher mortality (in-hospital: 9.1 % vs 4.8 %, Adjusted OR [95 % CI] = 1.70 [1.43-2.02], p < 0.001; 30-day mortality: 10.8 % vs 6 %, Adjusted HR [95 % CI] = 1.46 [1.26-1.68], p < 0.001) as compared to non-diabetes, particularly during the pandemic. CONCLUSIONS: Our study showed that in a contemporary STEMI population undergoing PPCI, diabetes is significantly associated with impaired epicardial reperfusion that translates into higher in-hospital and 30-day mortality, particularly during the pandemic.
No takes yet. Share an insight, caveat, or question.
Algowhary et al. (2024) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=16,083). Diabetes vs. Non-diabetes was evaluated on In-hospital mortality (Adjusted OR 1.70, 95% CI 1.43-2.02, p=<0.001). Diabetes was associated with a significantly higher in-hospital mortality compared to non-diabetes (9.1% vs 4.8%, adjusted OR 1.70) in patients with STEMI undergoing primary percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: